CD44 targeted delivery of hyaluronic acid-coated polymeric nanoparticles against colorectal cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Buccafusca G, Proserpio I, Tralongo AC et al. Early colorectal cancer: diagnosis, treatment and survivorship care. Crit. Rev. Oncol. Hematol. 136, 20–30 (2019).
  MedlineGoogle Scholar
• 2. Teixido C, Castillo P, Martinez-Vila C et al. Molecular markers and targets in melanoma. Cells 10(9), 2320 (2021).
  Medline CASGoogle Scholar
• 3. Sarandria N. A literature review in immuno-oncology: pathophysiological and clinical features of colorectal cancer and the role of the doctor–patient interaction. J. Cancer Ther. 13(12), 654–684 (2022).
  CASGoogle Scholar
• 4. Lewandowska A, Religioni U, Czerw A et al. Nutritional treatment of patients with colorectal cancer. Int. J. Environ. Res. Public Health 19(11), 6881 (2022).
  Medline CASGoogle Scholar
• 5. Chavda J, Bhatt H. Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. Eur. J. Med. Chem. 206, 112675 (2020).
  Medline CASGoogle Scholar
• 6. Yosef H, Frick T, Hammoud M et al. Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. Analyst 143(24), 6069–6078 (2018).
  Medline CASGoogle Scholar
• 7. Ahiwale RJ, Chellampillai B, Pawar AP. Investigation of novel sorafenib tosylate loaded biomaterial based nano-cochleates dispersion system for treatment of hepatocellular carcinoma. J. Dispersion Sci. Technol. 43(10), 1568–1586 (2022).
  CASGoogle Scholar
• 8. Pratt RL. Hyaluronan and the fascial frontier. Int. J. Mol. Sci. 22(13), 6845 (2021).
  Medline CASGoogle Scholar
• 9. Castaño-Amores C, Nieto-Gómez P, Nieto-Sánchez MT, Álvarez-Sánchez R. Práctica clínica en prevención de migraña con anticuerpos monoclonales del péptido relacionado con el gen calcitonina: evidencias de casos reales. Ars Pharmaceutica 63(4), 311–319 (2022).
  CASGoogle Scholar
• 10. Lee SY, Kang MS, Jeong WY et al. Hyaluronic acid-based theranostic nanomedicines for targeted cancer therapy. Cancers 12(4), 940 (2020). •• Explores the development of hyaluronic acid (HA)-coated poly-lactic-co-glycolic acid–polysarcosine–sorafenib tosylate (PLGA–PSAR–SF) nanoparticles for targeted colon cancer therapy. These nanoparticles offer controlled drug release, enhanced cytotoxicity against HCT116 cells, improved in vivo pharmacokinetics, targeting and biocompatibility, making them promising for colorectal therapy. The article findings have significant influence on our work.
  Medline CASGoogle Scholar
• 11. Settanni G, Schäfer T, Muhl C et al. Poly-sarcosine and poly (ethylene-glycol) interactions with proteins investigated using molecular dynamics simulations. Comput. Struct. Biotechnol. J. 16, 543–550 (2018).
  Medline CASGoogle Scholar
• 12. Wu F, Zhou Y, Li L et al. Computational approaches in preclinical studies on drug discovery and development. Front. Chem. 8, 726 (2020).
  Medline CASGoogle Scholar
• 13. Tiwari A, Modi SJ, Gabhe SY, Kulkarni VM. Evaluation of piperine against cancer stem cells (CSCs) of hepatocellular carcinoma: Insights into epithelial-mesenchymal transition (EMT). Bioorg. Chem. 110, 1–17 (2021).
  Google Scholar
• 14. Dhawan V, Lokras A, Joshi G et al. Polysaccharide and monosaccharide guided liver delivery of sorafenib tosylate –a nano-strategic approach and comparative assessment of hepatospecificity. Int. J. Pharm. 625, 1–16 (2022). •• Demonstrates targeted, efficient SF delivery using nanoparticles, enhancing cancer therapy precision and efficacy.
  Google Scholar
• 15. Giammona G, Drago SE, Calabrese G et al. Galactosylated polymer/gold nanorods nanocomposites for sustained and pulsed chemo-photothermal treatments of hepatocarcinoma. Pharmaceutics 14(11), 2503 (2022).
  Medline CASGoogle Scholar
• 16. Bhattacharya S, Anjum MM, Patel KK. Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery. Drug Deliv. 29(1), 1060–1074 (2022). •• Explores similar nanoparticle-based targeted drug-delivery strategies for cancer treatment.
  Medline CASGoogle Scholar
• 17. Almoustafa HA, Alshawsh MA, Al-Suede FSR et al. The chemotherapeutic efficacy of hyaluronic acid coated polymeric nanoparticles against breast cancer metastasis in female NCr-Nu/Nu nude mice. Polymers 15(2), 284 (2023). •• Demonstrates the effectiveness of HA-coated polymeric nanoparticles in inhibiting breast cancer metastasis in mice, offering potential insights for our research in nanoparticle-based cancer treatments.
  Medline CASGoogle Scholar
• 18. Kale SA, Shaikh KS. Validated UV-vis spectrophotometric method for the estimation of sorafenib tosylate in bulk and nanoparticles. Int. J. Health Sci. 6(Suppl. 3), 4011–4019 (2022).
  Google Scholar
• 19. Dahiya M, Awasthi R, Dua K, Dureja H. Sorafenib tosylate loaded superparamagnetic nanoparticles: development, optimization and cytotoxicity analysis on HepG2 human hepatocellular carcinoma cell line. J. Drug Deliv. Sci. Technol. 79, 1–19 (2023).
  Google Scholar
• 20. Li N, Chen Y, Sun H et al. Decreasing acute toxicity and suppressing colorectal carcinoma using sorafenib-loaded nanoparticles. Pharm. Dev. Technol. 25(5), 556–565 (2020).
  Medline CASGoogle Scholar
• 21. Caputo TM, Cusano AM, Principe S et al. Sorafenib-loaded PLGA carriers for enhanced drug delivery and cellular uptake in liver cancer cells. Int. J. Nanomed. 18, 4121–4142 (2023).
  Medline CASGoogle Scholar
• 22. Shukla SK, Kulkarni NS, Farrales P et al. Sorafenib loaded inhalable polymeric nanocarriers against non-small-cell lung cancer. Pharm. Res. 37, 1–19 (2020). • Presents the development of inhalable polymeric nanocarriers for delivering sorafenib.
  Google Scholar
• 23. Gao X, Jiang P, Zhang Q et al. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma. J. Exp. Clin. Cancer Res. 38(1), 1–15 (2019).
  MedlineGoogle Scholar
• 24. Wu H, Wang C, Sun J et al. Self-assembled and self-monitored sorafenib/indocyanine green nanodrug with synergistic antitumor activity mediated by hyperthermia and reactive oxygen species-induced apoptosis. ACS Appl. Mater. Interfaces 11(47), 43996–44006 (2019).
  Medline CASGoogle Scholar
• 25. Poojari R, Sawant AV, Kini S et al. Antihepatoma activity of multifunctional polymeric nanoparticles via inhibition of microtubules and tyrosine kinases. Nanomedicine 15(04), 381–396 (2020).
  CASGoogle Scholar
• 26. Varshosaz J, Sadri F, Rostami M et al. Synthesis of pectin-deoxycholic acid conjugate for targeted delivery of anticancer drugs in hepatocellular carcinoma. Int. J. Biol. Macromol. 139, 665–677 (2019).
  Medline CASGoogle Scholar
• 27. Palomba F, Genovese D, Rampazzo E et al. PluS nanoparticles loaded with sorafenib: synthetic approach and their effects on endothelial cells. ACS Omega 4(9), 13962–13971 (2019).
  Medline CASGoogle Scholar
• 28. Sarwar U, Naeem M, Nurjis F et al. Ultrasound-mediated in vivo biodistribution of coumarin-labeled sorafenib-loaded liposome-based nanotheranostic system. Nanomedicine 17(25), 1909–1927 (2022).
  CASGoogle Scholar
• 29. Gopakumar L, Sreeranganathan M, Chappan S et al. Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core–shell protein nanoparticle. Drug Deliv. Transl. Res. 12(11), 2824–2837 (2022).
  Medline CASGoogle Scholar
• 30. Donthi MR, Munnangi SR, Krishna KV et al. Formulating ternary inclusion complex of sorafenib tosylate using β-cyclodextrin and hydrophilic polymers: physicochemical characterization and in vitro assessment. AAPS PharmSciTech 23(7), 254 (2022).
  Medline CASGoogle Scholar
• 31. Xiao B, Han MK, Viennois E et al. Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale 7(42), 17745–17755 (2015).
  Medline CASGoogle Scholar
• 32. Bertrand N, Wu J, Xu X et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014).
  Medline CASGoogle Scholar
• 33. Babos G, Biró E, Meiczinger M, Feczkó T. Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers 10(8), 895 (2018).
  MedlineGoogle Scholar
• 34. Abdellatif AA, Ali AT, Bouazzaoui A et al. Formulation of polymeric nanoparticles loaded sorafenib; evaluation of cytotoxicity, molecular evaluation, and gene expression studies in lung and breast cancer cell lines. Nanotechnol. Rev. 11(1), 987–1004 (2022).
  CASGoogle Scholar
• 35. Kalepu S, Nekkanti V. Improved delivery of poorly soluble compounds using nanoparticle technology: a review. Drug Deliv. Transl. Res. 6, 319–332 (2016).
  Medline CASGoogle Scholar
• 36. Poojari R, Kini S, Srivastava R, Panda D. Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells. Colloids Surf. B Biointerfaces 143, 131–138 (2016).
  Medline CASGoogle Scholar
• 37. Guan Q, Guo R, Huang S et al. Mesoporous polydopamine carrying sorafenib and SPIO nanoparticles for MRI-guided ferroptosis cancer therapy. J. Control. Rel. 320, 392–403 (2020).
  Medline CASGoogle Scholar
• 38. Hu B, Sun D, Sun C et al. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 468(4), 525–532 (2015).
  Medline CASGoogle Scholar
• 39. Bahman A, Abaza M-S, Khoushaish S, Al-Attiyah RJ. Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells. BMC Complement. Med. Ther. 23(1), 1–24 (2023).
  Google Scholar
• 40. Chen Y, Li N, Xu B et al. Polymer-based nanoparticles for chemo/gene-therapy: evaluation its therapeutic efficacy and toxicity against colorectal carcinoma. Biomed. Pharmacother. 118, 1–19 (2019).
  Google Scholar
• 41. Lazzari S, Moscatelli D, Codari F et al. Colloidal stability of polymeric nanoparticles in biological fluids. J. Nanoparticle Res. 14, 1–10 (2012).
  Google Scholar
• 42. Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Crit. Rev. Oncol. Hematol. 88(3), 504–513 (2013).
  MedlineGoogle Scholar